Cancer Immunotherapy Market : Analysis of Potential Market Opportunity Worth $119.39 Billion by 2022
According to a new market research "Cancer Immunotherapy Market
by Type (Monoclonal Antibodies, Cancer Vaccines, Check Point Inhibitors
& Immunomodulators), Application (Lung, Breast, Colorectal,
Melanoma, Prostate, Head & Neck), End User (Hospital and Clinics) -
Global Forecast to 2021", published by MarketsandMarkets, the global
Cancer Immunotherapy Market is expected to reach USD 119.39 Billion by
2021 from USD 61.9 Billion in 2016, at a CAGR of 14.0% from 2016 to
2021.
This growth can be attributed to factors such as
increasing adoption of target therapy over traditional therapy,
emergence of biosimilars, increasing demand for mAbs, high prevalence of
cancer.
This report aims to provide insights into the global
cancer immunotherapy market. It provides valuable information on type,
application, end user. Details on regional markets for these segments
have also been presented in this report. In addition, leading players in
the market are profiled to understand the strategies undertaken by them
to be competitive in this market.
Browse 43 market data Tables and 69 Figures spread through 145 Pages and in-depth TOC on "Cancer Immunotherapy Market"
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=197577894
In
this report, the global Cancer Immunotherapy Market has been segmented
based on type, application, end user, and region. On the basis of type,
the market has been segmented into monoclonal antibodies, cancer
vaccines, checkpoint inhibitors, and immunomodulators. The monoclonal
antibodies segment is expected to account for the largest share of the
market in 2016, while the checkpoint inhibitors segment is projected to
witness the highest CAGR from 2016 to 2021. The high growth in this
segment is primarily attributed to the high success rate of these
inhibitors.
On the basis of end users, the global Cancer
Immunotherapy Market is segmented into hospitals and clinics &
others. The hospitals segment is expected to account for the largest
share of the global Cancer Immunotherapy Market in 2016. The rise in
healthcare spending has resulted in the increasing use of
immunotherapeutic drugs in hospitals.
On the basis of
applications, the global Cancer Immunotherapy Market is segmented into
lung cancer, breast cancer, colorectal cancer, melanoma, prostate
cancer, head & neck cancer, and others. The lung cancer segment is
expected to grow at the highest CAGR during the forecast period. The
high growth in this segment can be attributed to the increasing
prevalence of this type of cancer and rising demand for advanced
treatment options.
Based on regions, the global Cancer
Immunotherapy Market is segmented into North America, APAC, Europe, and
the Rest of the World (RoW). North America is expected to account for
the largest share of the market in 2016. Growth in this regional segment
is driven by factors such as increase in patient pool and initiative
taken by the government for the development of cancer immunotherapy.
Request For Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=197577894
Key
players in the Cancer Immunotherapy Market include Amgen (U.S.),
AstraZeneca (U.K.), F. Hoffmann-La Roche AG (Switzerland), Bayer AG
(Germany), Bristol-Myers Squibb (U.S.), Eli Lilly and Company (U.S.),
Janssen Global Services, LLC (Belgium), Merck (U.S.), Novartis
(Switzerland), and Pfizer (U.S.).
Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com
Comments
Post a Comment